NDA 212801 · Recordati Rare
Isturisa
Osilodrostat Phosphate · Oral
NovelOrphanLast checked: Nov 19, 2026Latest source record: Nov 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Mar 6, 2020
Approved uses
3
Original approval plus efficacy supplements
Registered trials
19
2 Phase 3, 6 recruiting
FAERS reports
2,214
1,554 serious, 294 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 18, 2025.
ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative ( 1 )
Mechanism: Osilodrostat is a cortisol synthesis inhibitor. It inhibits 11beta-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. In a Chinese hamster lung cell line V79-4 that overexpresses human CYP11B1, adrenodoxin and adrenodoxin reductase, osilodrostat inhibited the activity of human CYP11B1 dose-dependently with IC50 values of 2.5 ± 0.1 nM (n = 4).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 3, 2025 Supplement 4 · Efficacy OrphanLetterLabel
- Apr 15, 2025 Supplement 3 · Efficacy OrphanLetterLabel
- Mar 6, 2020 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
3 products under this application
- ISTURISA · OSILODROSTAT PHOSPHATE EQ 5MG BASE · TABLET, ORAL · Prescription
- ISTURISA · OSILODROSTAT PHOSPHATE EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- ISTURISA · OSILODROSTAT PHOSPHATE EQ 1MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Osilodrostat" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential HypertensionPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00758524 · 628 participants · Start Sep 11, 2008 · Primary completion Jul 2, 2009
Drug: LCI699; Eplerenone and 2 more · For: Essential Hypertension
Sites: East Hanover, New Jersey
- A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant HypertensionPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00817635 · 155 participants · Start Dec 22, 2008 · Primary completion Oct 13, 2009
Drug: LCI699; Eplerenone and 2 more · For: Hypertension
Sites: Mobile, Alabama; Sierra Vista, Arizona; Buena Park, California · 38 sites in all
- Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)Recruiting
Laikο General Hospital, AthensAcademic, hospital or other
NCT07268222 · 150 participants (planned) · Start Dec 1, 2025 · Primary completion Nov 1, 2026
Drug: Metyrapone 250 mg Oral Tablets; Osilodrostat 1 MG · For: Mild Autonomous Cortisol Secretion (MACS)
Sites: Athens, Greece
- Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseasePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02180217 · 137 participants · Start Oct 6, 2014 · Primary completion Feb 21, 2018
Drug: osilodrostat; LCI699 matching placebo · For: Cushings Disease
Sites: Aurora, Colorado; Atlanta, Georgia; Chicago, Illinois · 60 sites in all
RECORDATI GROUPIndustry
NCT03606408 · 127 participants · Start Oct 5, 2018 · Primary completion Nov 16, 2023
Drug: osilodrostat · For: Cushing's Syndrome
Sites: Aurora, Colorado; Atlanta, Georgia; Chicago, Illinois · 56 sites in all
- Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseasePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02697734 · 73 participants · Start Oct 3, 2016 · Primary completion Jun 19, 2019
Drug: osilodrostat; osilodrostat Placebo · For: Cushing's Disease
Sites: Aurora, Colorado; Ann Arbor, Michigan; New York, New York · 36 sites in all
NovartisNovartis (NVS)
NCT00817414 · 63 participants · Start Jan 14, 2009 · Primary completion Aug 12, 2009
Drug: LCI699-matching placebo; LCI699 · For: Hypertension
Sites: Beverly Hills, California; Buena Park, California; Harbor City, California · 11 sites in all
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeRecruiting
RECORDATI GROUPIndustry
NCT07247162 · 63 participants (planned) · Start Aug 26, 2026 · Primary completion May 2028
Drug: Osilodrostat; Placebo · For: Hypertension; Hypercortisolemia; Cushing Syndrome
Sites: Jacksonville, Florida; Canton, Ohio; Weslaco, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use376
- fatigue305
- nausea260
- death152
- adrenal insufficiency142
- headache142
- asthenia129
- diarrhoea125
- dizziness120
- decreased appetite114
- vomiting109
- cortisol decreased88
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2020 | 160 |
| 2021 | 148 |
| 2022 | 268 |
| 2023 | 281 |
| 2024 | 400 |
| 2025 | 544 |
| 2026 | 412 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Isturisa (Osilodrostat Phosphate)
2024 spending
$65.5M
Beneficiaries
328
2,284 claims
Per beneficiary
$199,763
$249.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,176,243 |
| 2021 | $9,457,234 |
| 2022 | $17,110,721 |
| 2023 | $34,621,980 |
| 2024 | $65,522,308 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
Gadelha M, Bex M, Feelders RA, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase III, Multicenter Study
- Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors-A Systematic Review.
Rasmussen AA, Nordestgaard KL, Simonsen U, et al. · Basic Clin Pharmacol Toxicol 2025 · Systematic Review
- Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R, Fleseriu M, Newell-Price J, et al. · Lancet Diabetes Endocrinol 2020 · Clinical Trial, Phase III, Multicenter Study
- Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.
Fleseriu M, Pivonello R, Lacroix A, et al. · Eur J Endocrinol 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Aldosterone Synthase Inhibitors for Resistant Hypertension: Pharmacological Insights - A Systematic Review.
Cicero AFG, Tocci G, Avagimyan A, et al. · Drugs 2025 · Systematic Review
- Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
Fleseriu M, Pivonello R, Young J, et al. · Pituitary 2016 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Recordati Rare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.